Lymphocytic Leukemia, Chronic
Oncology·MeSH: Leukemia, Lymphocytic, Chronic, B-Cell
Prevalence
30.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Obinutuzumab | AbbVie Inc. (ABBV) |
Frequently asked questions
How many drugs are in development for Lymphocytic Leukemia, Chronic?
BioSniper tracks 1 drug in development for Lymphocytic Leukemia, Chronic across 1 company.
How many clinical trials target Lymphocytic Leukemia, Chronic?
There are 1 clinical trial targeting Lymphocytic Leukemia, Chronic tracked by BioSniper.
What is the prevalence of Lymphocytic Leukemia, Chronic?
The estimated prevalence of Lymphocytic Leukemia, Chronic is approximately 30.0 per 100,000 population.
Deep-dive into Lymphocytic Leukemia, Chronic
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis